Evidence Supporting Revised Indications for Metabolic and Bariatric Surgery
Overview
This report summarizes the updated evidence-based recommendations for metabolic and bariatric surgery (MBS) indications, reflecting advances since the 1991 NIH criteria. Systematic reviews and expert consensus support expanding MBS candidacy to patients with BMI 30–34.9 kg/m2 with comorbidities and highlight improved safety and efficacy outcomes.
Background
Since the mid-1950s, gastrointestinal surgery for obesity has evolved significantly, with early procedures marked by high risks and inconsistent guidelines. The 1991 NIH consensus established initial criteria for MBS candidacy, but these have not been updated despite advances in surgical techniques, perioperative care, and new procedures like sleeve gastrectomy. In 2022, ASMBS and IFSO collaborated to revise these guidelines using systematic reviews and expert Delphi consensus to reflect current evidence and global practice.
MBS is recommended for patients with BMI 30–34.9 kg/m2 who have type 2 diabetes mellitus (T2DM) or at least one obesity-associated medical problem.
MBS should be considered for patients with BMI 30–34.9 kg/m2 who fail to achieve durable weight loss or comorbidity improvement with nonsurgical methods.
Operative time and length of hospital stay for patients with BMI 30–34.9 kg/m2 are comparable to those with BMI ≥35 kg/m2.
Complication rates vary by procedure, with revisional surgeries showing higher rates; overall mortality is very low or absent.
Remission rates for T2DM and hypertension after MBS in this BMI group range widely but can be as high as 100%.
Systematic reviews and Delphi consensus were used to address gaps in evidence, ensuring recommendations are evidence-based and globally relevant.
Clinical Implications
Clinicians should consider MBS for patients with BMI 30–34.9 kg/m2 who have T2DM or other obesity-related conditions, expanding beyond the traditional BMI ≥35 threshold. Surgical safety and efficacy data support offering MBS to these patients, with careful patient selection and multidisciplinary management. This approach may improve long-term metabolic outcomes and reduce obesity-associated morbidity.
Conclusion
Updated evidence supports revising MBS indications to include patients with BMI 30–34.9 kg/m2 with comorbidities, reflecting advances in surgical safety and efficacy. These guidelines provide a more inclusive, evidence-based framework for patient selection in metabolic and bariatric surgery.
References
ASMBS/IFSO 2022 -- Evidence Supporting Revised Recommendations for Metabolic and Bariatric Surgery Indications
by Maurizio De Luca, Scott Shikora, Dan Eisenberg, Luigi Angrisani, Chetan Parmar, Aayed Alqahtani, Ali Aminian, Edo Aarts, Wendy Brown, Ricardo V. Cohen, Nicola Di Lorenzo, Silvia L. Faria, Kasey P. S. Goodpaster, Ashraf Haddad, Miguel Herrera, Raul Rosenthal, Jacques Himpens, Angelo Iossa, Mohammad Kermansaravi, Lilian Kow, Marina Kurian, Sonja Chiappetta, Teresa LaMasters, Kamal Mahawar, Giovanni Merola, Abdelrahman Nimeri, Mary O’Kane, Pavlos Papasavas, Giacomo Piatto, Jaime Ponce, Gerhard Prager, Janey S. A. Pratt, Ann M. Rogers, Paulina Salminen, Kimberley E. Steele, Michel Suter, Salvatore Tolone, Antonio Vitiello, Marco Zappa, Shanu N. Kothari
FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.
